GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » Shiller PE Ratio
中文

PTC Therapeutics (PTC Therapeutics) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2013. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


PTC Therapeutics Shiller PE Ratio Historical Data

The historical data trend for PTC Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PTC Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Shiller PE Ratio falls into.



PTC Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PTC Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, PTC Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.06/129.4194*129.4194
=-2.060

Current CPI (Dec. 2023) = 129.4194.

PTC Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.580 99.695 -0.753
201406 -0.860 100.560 -1.107
201409 -0.930 100.428 -1.198
201412 -0.840 99.070 -1.097
201503 -1.150 99.621 -1.494
201506 -1.140 100.684 -1.465
201509 -1.270 100.392 -1.637
201512 -1.500 99.792 -1.945
201603 -1.220 100.470 -1.572
201606 -1.140 101.688 -1.451
201609 -1.030 101.861 -1.309
201612 -0.780 101.863 -0.991
201703 -0.850 102.862 -1.069
201706 -0.440 103.349 -0.551
201709 -0.820 104.136 -1.019
201712 0.030 104.011 0.037
201803 -0.460 105.290 -0.565
201806 -0.210 106.317 -0.256
201809 -1.060 106.507 -1.288
201812 -0.960 105.998 -1.172
201903 -1.290 107.251 -1.557
201906 -0.750 108.070 -0.898
201909 -1.060 108.329 -1.266
201912 -1.370 108.420 -1.635
202003 -1.810 108.902 -2.151
202006 -2.780 108.767 -3.308
202009 -1.030 109.815 -1.214
202012 -1.050 109.897 -1.237
202103 -1.830 111.754 -2.119
202106 -1.680 114.631 -1.897
202109 -1.890 115.734 -2.113
202112 -2.030 117.630 -2.233
202203 -1.780 121.301 -1.899
202206 -2.130 125.017 -2.205
202209 -1.530 125.227 -1.581
202212 -2.350 125.222 -2.429
202303 -1.880 127.348 -1.911
202306 -2.660 128.729 -2.674
202309 -1.760 129.860 -1.754
202312 -2.060 129.419 -2.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PTC Therapeutics  (NAS:PTCT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PTC Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics (PTC Therapeutics) Business Description

Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Neil Gregory Almstead officer: EVP Research Pharma Ops & Tech C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Matthew B. Klein officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Mark Elliott Boulding officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Eric Pauwels officer: Chief Business Officer 550 HILLS DRIVE, BEDMINSTER NJ 07921
Christine Marie Utter officer: Principal Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Lee Scott Golden officer: Chief Medical Officer 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Michael Schmertzler director 110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Pierre Gravier officer: CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr. director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Allan Steven Jacobson director PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
David P Southwell director C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Emily Luisa Hill officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Stuart Walter Peltz director, officer: Chief Executive Officer PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080